Results 71 to 80 of about 28,235,749 (276)

Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. [PDF]

, 2011
The autoimmune form of atypical hemolytic uremic syndrome (HUS) is characterized by circulating autoantibodies against the complement regulator factor H, and is often associated with deficiency of the factor H-related proteins CFHR1 and CFHR3.
Stefanie Strobel, Abarrategui-Garrido, C., Sanchez-Corral, P., Mihály Józsi, Strobel, S., Elena Fariza-Requejo, Seeberger, H., Cynthia Abarrategui-Garrido, Józsi, Mihály, Fariza-Requejo, E., Harald Seeberger, Pilar Sánchez-Corral   +11 more
core   +1 more source

FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy

Frontiers in Immunology, 2021
BackgroundFactor H-related protein 5 (FHR-5) is a member of the complement Factor H protein family. Due to the homology to Factor H, the main complement regulator of the alternative pathway, it may also be implicated in the pathomechanism of kidney ...
Nóra Garam, Marcell Cserhalmi, Zoltán Prohászka, Zoltán Prohászka, Ágnes Szilágyi, Nóra Veszeli, Nóra Veszeli, Edina Szabó, Barbara Uzonyi, Attila Iliás, Christof Aigner, Alice Schmidt, Martina Gaggl, Gere Sunder-Plassmann, Dóra Bajcsi, Jürgen Brunner, Alexandra Dumfarth, Daniel Cejka, Stefan Flaschberger, Hana Flögelova, Ágnes Haris, Ágnes Hartmann, Andreas Heilos, Thomas Mueller, Krisztina Rusai, Klaus Arbeiter, Johannes Hofer, Johannes Hofer, Johannes Hofer, Dániel Jakab, Mária Sinkó, Erika Szigeti, Csaba Bereczki, Viktor Janko, Kata Kelen, György S. Reusz, Attila J. Szabó, Nóra Klenk, Krisztina Kóbor, Nika Kojc, Maarten Knechtelsdorfer, Mario Laganovic, Adrian Catalin Lungu, Anamarija Meglic, Rina Rus, Tanja Kersnik Levart, Ernesta Macioniene, Marius Miglinas, Anna Pawłowska, Tomasz Stompór, Ludmila Podracka, Michael Rudnicki, Gert Mayer, Romana Rysava, Jana Reiterova, Marijan Saraga, Marijan Saraga, Tomáš Seeman, Jakub Zieg, Eva Sládková, Natasa Stajic, Tamás Szabó, Andrei Capitanescu, Simona Stancu, Miroslav Tisljar, Kresimir Galesic, András Tislér, Inga Vainumäe, Martin Windpessl, Tomas Zaoral, Galia Zlatanova, Mihály Józsi, Mihály Józsi, Dorottya Csuka, Dorottya Csuka   +74 more
doaj   +1 more source

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

FEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens, Brendan W. Chandler, Anna M. Schmoker, Jaye L. Weinert, Charlotte A. Kearns, Warren T. Yacawych, Amila Šemić, Alicia M. Ebert, Bryan A. Ballif   +8 more
wiley   +1 more source

Complement Factor H: solution structures and interactions with ligands [PDF]

, 2009
Factor H (FH) is a plasma glycoprotein that plays a central role in regulating the alternative pathway of complement. It is composed of 20 short complement regulator (SCR) domains.
Okemefuna, A.I.
core  

Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. [PDF]

PLoS Genetics, 2007
Atypical hemolytic uremic syndrome (aHUS) is associated with defective complement regulation. Disease-associated mutations have been described in the genes encoding the complement regulators complement factor H, membrane cofactor protein, factor B, and ...
Peter F Zipfel, Matthew Edey, Stefan Heinen, Mihály Józsi, Heiko Richter, Joachim Misselwitz, Bernd Hoppe, Danny Routledge, Lisa Strain, Anne E Hughes, Judith A Goodship, Christoph Licht, Timothy H J Goodship, Christine Skerka   +13 more
doaj   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Self-association of complement factor H in the presence and absence of metals [PDF]

, 2010
In the complement system of innate immunity, factor H (FH) is a major regulator of its activation, and is comprised of 20 short complement regulator (SCR) domains.
Nan, R.
core  

Sequence Motifs in MADS Transcription Factors Responsible for Specificity and Diversification of Protein-Protein Interaction [PDF]

, 2010
Protein sequences encompass tertiary structures and contain information about specific molecular interactions, which in turn determine biological functions of proteins.
Angenent, G.C., Martijn Fiers, Roeland C H J van Ham, Roeland C. H. J. van Ham, Morabito Giuseppa, Ham, R.C.H.J., van, Aalt D J van Dijk, Angenent Gerco C., Immink, R.G.H., Richard G H Immink, van Dijk Aalt D. J., Morabito, G., van Ham Roeland C. H. J., Dijk, A.D.J., van, Fiers, M.A., Richard G. H. Immink, Giuseppa Morabito, Aalt D. J. van Dijk, Immink Richard G. H., Gerco C Angenent, Gerco C. Angenent, Fiers Martijn   +21 more
core   +2 more sources

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source